Pacific Biosciences of California Inc. (NASDAQ:PACB) saw a downside of -1.81% to $23.86 after subtracting -$0.44 on Wednesday. The 5-day average trading volume is 1,411,769 shares of the company’s common stock. It has gained $26.19 in the past week. An average of 1,805,702 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 1,750,857.
PACB’s 1-month performance is -14.65% or -$4.55 on its low of $23.61 reached on 10/06/21. The company’s shares have touched a 52-week low of $11.22 and high of $53.69, with the stock’s rally to the 52-week high happening on 02/11/21. YTD, PACB has lost -6.32% or -$2.02. However, the current price is down -55.56%% from the 52-week high price.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
On Sep 29, 14 days have gone by since the last insider trading activity for Pacific Biosciences of California Inc. (PACB). Kim Susan G. (Chief Financial Officer) most recently sold 20,272 shares at $25.75 per share on Sep 29. This transaction cost the insider $522,004. President & CEO, HENRY CHRISTIAN O, sold 90,520 shares at a price of $26.91 on Sep 16. Then, on May 25, Director Ericson William W. sold 37,500 shares at a price of $25.89 per share. This transaction amounted to $971,058.
Pacific Biosciences of California Inc. (PACB) has a trailing price-to-earnings (P/E) ratio of 26.50 for the broader industry and 32.24 for the sector. The company’s PE ratio for the last five years has touched a high of 568.33 and a low of 288.22. PACB stock has a beta of 1.13. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 46.96 while the price-to-book (PB) in the most recent quarter is 18.69.
Pacific Biosciences of California Inc.’s quick ratio for the period ended June 29 was 25.80, with the current ratio over the same period at 26.20 meaning that PACB stock is able to fulfill its debt obligations. As well, the company’s long term debt to equity for the quarter ending June 29 was 3.47, while the total debt to equity was 0.00. In terms of profitability, the gross margin trailing 12 months is 42.70%. The trailing 12-month EBITDA margin is -120.52% while for the period ending June 29; Pacific Biosciences of California Inc.’s operating margin was -69.40%. The firm’s gross profit as reported stood at $32.57 million against revenue of $78.89 million.
For the quarterly period ending June 29 this year, Pacific Biosciences of California Inc.’s cash and short-term investments amounted to $684.58 million against total debt of $935.84 million. Net income and sales went up compared to those figures reported in the previous quarter. Analysts expected PACB to announce -$0.21 per share in earnings in its latest quarter, but it posted -$0.21, representing a 0.00% surprise. EBITDA for the quarter stood at more than -$33.81 million. PACB stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 987.54 million, with total debt at $935.84 million. Shareholders hold equity totaling $199.0 million
Let’s look briefly at Pacific Biosciences of California Inc. (PACB) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 12 October was 37.89% to suggest the stock is trending Neutral, with historical volatility in this time period at 62.02%.
The stock’s 5-day moving average is $24.53, reflecting a +0.23% or $0.05 change from its current price. PACB is currently trading -13.44% above its 20-day SMA, -6.43% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by -20.80% and -12.49% respectively.
Stochastic %K and %D was 11.05% and 17.54% and the average true range (ATR) pointed at 1.36. The RSI (14) points at 38.82%, while the 14-day stochastic is at 8.29% with the period’s ATR at 1.43. The stock’s 9-day MACD Oscillator is pointing at -0.58 and -0.84 on the 14-day charts.
In the most recent analyst report for Pacific Biosciences of California Inc. (NASDAQ: PACB), Canaccord Genuity launched coverage with a Buy rating. Analysts offering their rating for PACB stock have a consensus rating for the stock as Overweight. Currently, 0 brokerage advisors rate PACB as a “sell,”, while 2 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 3 have offered a “buy” rating.
What is PACB’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $30.00 and a high of $62.00, with their median price target at $45.00. Looking at these predictions, the average price target given by analysts is for Pacific Biosciences of California Inc. (PACB) stock is $45.60.